These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38056694)

  • 1. Prostate volume variation during 1.5T MR-guided adaptive stereotactic body radiotherapy (SBRT) and correlation with treatment toxicity.
    Nicosia L; Ravelli P; Rigo M; Giaj-Levra N; Mazzola R; Pastorello E; Ricchetti F; Allegra AG; Ruggieri R; Alongi F
    Radiother Oncol; 2024 Jan; 190():110043. PubMed ID: 38056694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
    Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
    Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linac-based versus MR-guided SBRT for localized prostate cancer: a comparative evaluation of acute tolerability.
    Nicosia L; Mazzola R; Rigo M; Giaj-Levra N; Pastorello E; Ricchetti F; Vitale C; Figlia V; Cuccia F; Ruggieri R; Alongi F
    Radiol Med; 2023 May; 128(5):612-618. PubMed ID: 37055672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis.
    Pham J; Neilsen BK; Liu H; Cao M; Yang Y; Sheng K; Ma TM; Kishan AU; Ruan D
    Med Phys; 2024 Jan; 51(1):612-621. PubMed ID: 38055353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
    Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
    BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes.
    Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Vitale C; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
    Br J Radiol; 2021 Jan; 94(1117):20200848. PubMed ID: 33095659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases.
    Cuccia F; Rigo M; Gurrera D; Nicosia L; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Attinà G; Pastorello E; De Simone A; Naccarato S; Sicignano G; Ruggieri R; Alongi F
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3269-3277. PubMed ID: 34268583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive SBRT by 1.5 T MR-linac for prostate cancer: On the accuracy of dose delivery in view of the prolonged session time.
    Ruggieri R; Rigo M; Naccarato S; Gurrera D; Figlia V; Mazzola R; Ricchetti F; Nicosia L; Giaj-Levra N; Cuccia F; Vitale C; Stavreva N; Pressyanov DS; Stavrev P; Pellegrini R; Alongi F
    Phys Med; 2020 Dec; 80():34-41. PubMed ID: 33091796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of adaptive planning in margin-reduced, MRI-guided stereotactic body radiotherapy to the prostate bed following radical prostatectomy: Post-hoc analysis of a phase II clinical trial.
    Nikitas J; Smith LM; Gao Y; Ma TM; Sachdeva A; Yoon SM; Jiang T; Low DA; Ballas LK; Steinberg ML; Cao M; Kishan AU
    Radiother Oncol; 2023 Jun; 183():109631. PubMed ID: 36934894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy.
    Nicosia L; Sicignano G; Rigo M; Figlia V; Cuccia F; De Simone A; Giaj-Levra N; Mazzola R; Naccarato S; Ricchetti F; Vitale C; Ruggieri R; Alongi F
    Acta Oncol; 2021 Feb; 60(2):215-221. PubMed ID: 32945701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SBRT focal dose intensification using an MR-Linac adaptive planning for intermediate-risk prostate cancer: An analysis of the dosimetric impact of intra-fractional organ changes.
    Brennan VS; Burleson S; Kostrzewa C; Godoy Scripes P; Subashi E; Zhang Z; Tyagi N; Zelefsky MJ
    Radiother Oncol; 2023 Feb; 179():109441. PubMed ID: 36549340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer.
    Schaule J; Chamberlain M; Wilke L; Baumgartl M; Krayenbühl J; Zamburlini M; Mayinger M; Andratschke N; Tanadini-Lang S; Guckenberger M
    Radiat Oncol; 2021 Sep; 16(1):189. PubMed ID: 34565439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation-induced prostate swelling during SBRT of the prostate.
    Vanhanen A; Reinikainen P; Kapanen M
    Acta Oncol; 2022 Jun; 61(6):698-704. PubMed ID: 35435111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Adaptive MR-Guided Radiotherapy for Prostate SBRT: Less Time, Equal Results.
    Sandoval ML; Youssef I; Latifi K; Grass GD; Torres-Roca J; Rosenberg S; Yamoah K; Johnstone PA
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
    Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
    Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy.
    Sandoval ML; Rishi A; Latifi K; Grass GD; Torres-Roca J; Rosenberg SA; Yamoah K; Johnstone PAS
    Cancer Control; 2024; 31():10732748241270595. PubMed ID: 39206515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy.
    Cuccia F; Mazzola R; Nicosia L; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Mantoan B; De Simone A; Sicignano G; Ruggieri R; Cavalleri S; Alongi F
    Radiat Oncol; 2020 Jul; 15(1):178. PubMed ID: 32698843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dosimetric error due to uncorrected tumor rotation during real-time adaptive prostate stereotactic body radiation therapy.
    Sengupta C; Skouboe S; Ravkilde T; Poulsen PR; Nguyen DT; Greer PB; Moodie T; Hardcastle N; Hayden AJ; Turner S; Siva S; Tai KH; Martin J; Booth JT; O'Brien R; Keall PJ
    Med Phys; 2023 Jan; 50(1):20-29. PubMed ID: 36354288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulated bladder wall dose is correlated with patient-reported acute urinary toxicity in prostate cancer patients treated with stereotactic, daily adaptive MR-guided radiotherapy.
    Willigenburg T; van der Velden JM; Zachiu C; Teunissen FR; Lagendijk JJW; Raaymakers BW; de Boer JCJ; van der Voort van Zyp JRN
    Radiother Oncol; 2022 Jun; 171():182-188. PubMed ID: 35489444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.